|
Less Volume and Reduced Viscosity Megace ES has 75% less total volume per dose compared with original formula Megace®.*1,17 Megace ES is also 94% less viscous than original formula Megace.6 This may be important for patients who are struggling with their ability and desire to eat. • Megace ES is substantially less viscous than some common OTC products, including Mylanta®† 6 • Lower viscosity may make Megace ES easier to take and may be important for patients who have trouble swallowing
*Megestrol acetate oral suspension. †Mylanta is a registered trademark of Johnson & Johnson-Merck Consumer Pharmaceuticals Co.
|
Indication
Megace ES (megestrol acetate) is a concentrated suspension indicated for the treatment of anorexia (loss of appetite),
cachexia (severe malnutrition), or an unexplained, significant weight loss in people with a diagnosis of AIDS.1
Megace ES is available by Prescription Only. For full Prescribing Information, click here.
*Adverse events greater than placebo derived from the comprehensive adverse events table (≥5%) in Megace ES and megestrol acetate oral suspension prescribing information.
NanoCrystal® is a registered trademark of Alkermes Pharma Ireland Limited.